Omentin-1 Levels and Non-alcoholic Fatty Liver Disease in Obese Adolescents
Open Access
- 13 October 2021
- journal article
- research article
- Published by Briefland in Iranian Journal of Pediatrics
- Vol. 31 (5)
- https://doi.org/10.5812/ijp.117353
Abstract
Background: Omentin-1 is an adipocytokine secreted from visceral adipose tissue that is thought to increase insulin sensitivity. Non-alcoholic fatty liver disease (NAFLD) is a comparatively extensive problem in obese adolescents. Decreased omentin-1 levels have been reported in obese patients, but the relationship between NAFLD and omentin-1 is contradictory. Objectives: We aimed to evaluate the omentin-1 levels in the sera of obese adolescents with and without NAFLD and compare them with each other. Methods: In this study, a total of 88 adolescents (56 obese and 32 normal-weight) were enrolled. Abdominal ultrasonography (US) identified 28 obese adolescents with grade 2-3 hepatosteatosis constituting the NAFLD group and 28 without hepatosteatosis on US constituting the non-NAFLD group. The control group included 32 age- and gender-matched cases without hepatosteatosis and with normal percentile body mass index (BMI). Serum omentin-1 levels were evaluated and compared. Results: The mean age of the research group was 12.72 ± 1.91 years. Unsurprisingly, BMI, glycated hemoglobin (HbA1c), liver transaminases (AST, ALT), total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL), homeostatic model assessment for insulin resistance (HOMA-IR), and insulin rates were noticeably elevated in obese adolescents compared to controls (P < 0.05). However, omentin-1 and high-density lipoprotein cholesterol (HDL) levels were remarkably lower in the obese group (P < 0.05). No significant difference was found between the NAFLD and non-NAFLD groups regarding omentin-1, HbA1c, glucose, urea, creatinine, AST, C-reactive protein (CRP), total cholesterol, triglyceride, HDL, LDL, thyroid stimulating hormone, 25-hydroxyvitamin D3, HOMA-IR, and insulin. The BMI and ALT grades of the non-NAFLD group were notably lower than the NAFLD group (P < 0.05). While there was no significant difference between omentin-1 and other parameters in obese adolescents without NAFLD (P > 0.05), we found a significant difference between omentin-1 and BMI, AST, ALT, HOMA-IR, and insulin values in obese adolescents with NAFLD (P < 0.05). Conclusions: Omentin-1 levels were decreased in obese adolescents regardless of the presence of NAFLD. However, in obese patients with NAFLD, there was a significant difference between omentin-1 and several markers of obesity and insulin resistance. Keywords Adolescents Non-alcoholic Fatty Liver Disease Obesity Omentin-1Keywords
This publication has 30 references indexed in Scilit:
- New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese womenBMC Medical Genetics, 2011
- Waist Circumference and Mid-Upper Arm Circumference in Evaluation of Obesity in Children Aged Between 6 and 17 Years-Original ArticleJournal of Clinical Research in Pediatric Endocrinology, 2010
- Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver diseaseScandinavian Journal of Gastroenterology, 2010
- Circulating omentin concentration increases after weight lossNutrition & Metabolism, 2010
- Omentin-1, a Novel Adipokine, Is Decreased in Overweight Insulin-Resistant Women With Polycystic Ovary SyndromeDiabetes, 2008
- Omentin Plasma Levels and Gene Expression Are Decreased in ObesityDiabetes, 2007
- Combined diet and exercise intervention reverses the metabolic syndrome in middle‐aged males: results from the Oslo Diet and Exercise StudyScandinavian Journal of Medicine & Science in Sports, 2007
- Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin actionAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Overweight and obesity in preschool children from developing countriesInternational Journal of Obesity, 2000
- Chronic Subclinical Inflammation as Part of the Insulin Resistance SyndromeJournal of the American College of Cardiology, 2000